Printer Friendly
The Free Library
14,635,340 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Life Medical Sciences Inc. developing improved stability formulations of Cariel & Piliel; clinical trial to be modified; corrects erroneous Reuters report.


PRINCETON, N.J.--(BUSINESS WIRE)--Feb. 9, 1996--Life Medical Sciences Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:CHAI chai  
n.
A beverage made from spiced black tea, honey, and milk.



[Ultimately from Chinese (Mandarin) chá, tea.]
) Friday announced that it has prepared lyophilized ly·oph·i·lize  
tr.v. ly·oph·i·lized, ly·oph·i·liz·ing, ly·oph·i·liz·es
To freeze-dry (blood plasma or other biological substances).



[lyophil(ic) + -ize.
 (freeze-dried) formulations of Cariel(tm), a proposed product for wound healing, and Piliel(tm), a proposed product for hair regrowth Re`growth´   

n. 1. The act of regrowing; a second or new growth.
The regrowth of limbs which had been cut off.
- A. B. Buckley.
, for the purpose of extending their shelf-life and eliminating the need for refrigeration refrigeration, process for drawing heat from substances to lower their temperature, often for purposes of preservation. Refrigeration in its modern, portable form also depends on insulating materials that are thin yet effective. .

The Cariel pivotal trial is being modified to test the new formulation of Cariel and to eliminate the testing of Cariel on superficial wounds, concentrating on more serious wounds. In addition, the numbers of centers at which Cariel will be tested will be increased. The company anticipates that results from these studies will be available by mid-1997.

Earlier this week, Reuters erroneously reported that management changes took place at Life Medical Sciences Inc. They confused Life Medical Sciences Inc., Nasdaq symbol: CHAI, with Life Medical Technologies Inc., Nasdaq symbol: LFMD, where the changes actually occurred. There have been no new management changes at Life Medical Sciences Inc.

Life Medical Sciences Inc. is engaged in the development of cost-effective medical products. The company is developing other medical products, including Lipoel(tm) for the autotransplantation autotransplantation /au·to·trans·plan·ta·tion/ (-trans?plan-ta´shun) transfer of tissue from one part of the body to another part.

au·to·trans·plan·ta·tion
n.
 of fat; and Repel(tm), a resorbable adhesion barrier film used to prevent surgical adhesions.

CONTACT: South Coast Communications

Kent Broussard (investor relations), 714/252-8440

Owen Daley (media), 714/252-8440

or

Life Medical Sciences Inc.

Donald W. Fallon, 609/452-0707
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 9, 1996
Words:226
Previous Article:Fusion Systems receives multi-system photostabilizer order from major Pacific Rim chipmaker.
Next Article:PC World Online Expands Sales Team; Stephen Shore Joins as Director of Market Development.
Topics:



Related Articles
SuperGen Inc. Files IND For MitoExtra.
Life Medical Sciences announces latest study results of REPEL post operative adhesion barrier -- 100% successful.
Life Medical Sciences Inc. announces the extension and adjustment of warrants.
Life Medical Sciences receives U.S. patent for CARIEL Topical Wound Healing Gel; possible European product launch in 1998.
Life Medical Sciences Announces Successful U.S. Pre-Clinical Trial Results For RESOLVE; New Adhesion Barrier Solution 2X More Efficacious Than...
Ergo Science Completes Enrollment of Phase II Weight Loss Clinical Study in Obese Subjects.
Treatment Interruption: Serious Error in Press Report.(Reuters mistakenly said structured treatment interruption for AIDS patients is not effective)
OXiGENE Announces Publication of Patent Application for Enhanced Formulation of Combretastatin A4 Prodrug; Company In-Licensed Worldwide Rights from...
TOPICAL TRIAL OF MELANOTAN GETS UK REGULATORY APPROVAL.
Calando Pharmaceuticals, UCLA Medical Center, City of Hope Announce Plans to Conduct First Cancer Clinical Trial for RNAi Therapeutic.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles